Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$41.27
+0.7%
$41.28
$26.56
$50.85
$1.19B0.83491,732 shs205,800 shs
Envista Holdings Corporation stock logo
NVST
Envista
$21.15
-0.5%
$20.29
$14.22
$23.00
$3.53B12.14 million shs1.04 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$67.67
-1.1%
$80.86
$41.50
$90.32
$3.64B-2.561.64 million shs923,265 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$114.96
-1.5%
$120.24
$55.00
$172.78
$3.98B2.09998,422 shs665,581 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-3.39%+2.50%-0.56%+18.36%-11.24%
Envista Holdings Corporation stock logo
NVST
Envista
+0.10%+3.99%+4.60%+16.19%+15.81%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
+1.08%-1.99%-18.53%-6.59%+45.49%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-0.56%-1.76%+11.34%-8.77%-30.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1.8769 of 5 stars
3.40.00.00.02.02.50.6
Envista Holdings Corporation stock logo
NVST
Envista
3.5967 of 5 stars
2.23.00.03.82.40.01.9
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.565 of 5 stars
4.51.00.04.62.72.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.8863 of 5 stars
2.42.00.00.04.02.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.83
Moderate Buy$56.5036.90% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.92-1.05% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.08
Buy$115.0970.08% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.78
Moderate Buy$123.006.99% Upside

Current Analyst Ratings Breakdown

Latest ESTA, TMDX, SLNO, and NVST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00
8/25/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/20/2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
8/20/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$123.00
8/18/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00 ➝ $110.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $110.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$15.00 ➝ $18.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $19.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$166.02M7.20N/AN/A$0.79 per share52.24
Envista Holdings Corporation stock logo
NVST
Envista
$2.51B1.40$1.65 per share12.79$18.89 per share1.12
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$4.52 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M8.88$1.62 per share70.94$9.33 per share12.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$84.60M-$3.05N/AN/AN/A-49.89%-224.34%-25.53%11/6/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B$0.3266.0817.481.142.11%4.84%2.68%10/29/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9359.5780.39N/A13.49%28.02%8.64%10/27/2025 (Estimated)

Latest ESTA, TMDX, SLNO, and NVST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
9.71
2.84
1.67
Envista Holdings Corporation stock logo
NVST
Envista
0.46
2.44
2.08
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
9.17

Institutional Ownership

CompanyInstitutional Ownership
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
72.91%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
11.09%
Envista Holdings Corporation stock logo
NVST
Envista
0.66%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1,01828.97 million25.76 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300166.18 million165.09 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.70 millionOptionable

Recent News About These Companies

Nuveen LLC Buys New Stake in TransMedics Group, Inc. $TMDX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Establishment Labs stock logo

Establishment Labs NASDAQ:ESTA

$41.27 +0.27 (+0.66%)
Closing price 04:00 PM Eastern
Extended Trading
$40.40 -0.88 (-2.12%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Envista stock logo

Envista NYSE:NVST

$21.14 -0.11 (-0.49%)
Closing price 03:59 PM Eastern
Extended Trading
$21.18 +0.03 (+0.16%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$67.67 -0.74 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$67.19 -0.48 (-0.71%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$114.96 -1.76 (-1.51%)
Closing price 04:00 PM Eastern
Extended Trading
$115.46 +0.50 (+0.43%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.